The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving ChemoCentryx, Inc.

New York, New York – (Newsfile Corp. – June 2, 2021) – Vincent Wong’s law firms announce that a class action lawsuit has been initiated on behalf of investors who have purchased ChemoCentryx, Inc. (“ChemoCentryx”) ( NASDAQ: CCXI) between November 26, 2019 and May 3, 2021.

If you have suffered a loss, contact us at the link below. There are no costs or obligations for you.
http://www.wongesq.com/pslra-1/chemocentryx-inc-loss-submission-form?prid=16481&wire=5

The allegations against CCXI include that the company made essentially false and / or misleading statements and / or failed to disclose: (1) The study design of the Phase III ADVOCATE study raised problems with the interpretability of the study data define a clinically meaningful benefit of avacopan and its role in the treatment of ANCA-associated vasculitis; (2) data from the Phase III ADVOCATE trial raise serious safety concerns for avacopan; (3) these issues raised significant concerns about the feasibility of ChemoCentryx’s new drug application (“NDA”) for avacopan for the treatment of ANCA-associated vasculitis; and (4) as a result of the foregoing, Defendants’ public statements at all relevant times have been materially false and misleading.

If you have suffered damage at ChemoCentryx, you can apply until July 6, 2021 for the court to appoint you as the lead plaintiff. Your ability to partake in a recovery does not require you to be the lead plaintiff.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities disputes related to financial fraud and shareholder violations. Lawyer advertising. Previous results do not guarantee similar results.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Telephone number. 212.425.1140
Fax. 866.699.3880
Email: vw@wongesq.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/86224

Comments are closed.